The Phase 1/2 BEACON trial, which is testing the gene-editing cell therapy BEAM-101 in people with sickle cell disease…
Articles by Marisa Wexler, MS
An advisory committee to the U.S. Food and Drug Administration (FDA) has completed its meeting on exa-cel — formally exagamglogene…
If the U.S. Food and Drug Administration (FDA) approves the experimental sickle cell disease (SCD) gene therapy lovotibeglogene autotemcel…
The number of red blood cells that produce the abnormal hemoglobin S (HbS), which characterizes sickle cell disease (SCD),…
Point-of-care tests can be used to accurately diagnose sickle cell disease (SCD) in resource-limited settings such as sub-Saharan Africa,…
HPC International has released new editions of Hope & Destiny, a book series that aims to help people with sickle…
The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on FTX-6058, an investigational oral treatment for…
A gene editing technology called adenosine base editing (ABE), wherein a single DNA building block is changed to increase fetal…
The fourth annual Cheek Week, an effort to include more blood stem cell donors in the Be The Match…
The U.S. Food and Drug Administration (FDA) is expected to decide before year’s end on whether or not to approve…